BioRestorative awarded notice of allowance from JPO for ThermoStem platform

BioRestorative Therapies (BRTX) announced a major intellectual property milestone: the Japanese Patent Office, JPO, has issued a Notice of Allowance for the Company’s ThermoStem platform. The newly allowed patent provides broad protection for BioRestorative’s allogeneic, off-the-shelf brown adipose-derived stem cell technology, designed to treat obesity and metabolic disorders. These claims are materially stronger than previously granted patents, covering not only the therapeutic cells themselves, but also multiple methods of encapsulation and delivery – including alginate microcapsules, cellulose hydrogels, polymer membranes, and advanced scaffolding systems.